Mesoblast (MESO) Other Accumulated Expenses (2022 - 2025)
Mesoblast (MESO) posted quarterly Other Accumulated Expenses of $2.3 million for Q4 2025, up 502.08% year-on-year from $385000.0 in Q4 2024, and up 502.08% on a QoQ basis from $385000.0 in Q4 2024.
Mesoblast (MESO) Other Accumulated Expenses (2022 - 2025) Analysis & Trends
Mesoblast (MESO) has reported Other Accumulated Expenses for 4 consecutive years, with $2.3 million the latest figure, recorded in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,102.16 Bn | 67,101.87 Bn | - |
| 2 | Nanobiotix | 1,913.50 Bn | 1,913.44 Bn | - |
| 3 | Akari Therapeutics | 959.56 Bn | 959.56 Bn | - |
| 4 | BeOne Medicines | 473.74 Bn | 468.95 Bn | 1.35 Bn |
| 5 | Vertex Pharmaceuticals | 122.07 Bn | 114.82 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 70.00 Bn | 61.24 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.34 Bn | 62.34 Bn | - |
| 8 | Argenx Se | 55.96 Bn | 50.77 Bn | 1.41 Bn |
| 9 | Alnylam Pharmaceuticals | 37.49 Bn | 34.48 Bn | 959.66 Mn |
| 10 | Mesoblast | 18.89 Bn | 18.76 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 2.32 Mn |
| Dec 31, 2024 | 385,000.00 |
| Dec 31, 2023 | 367,000.00 |
| Mar 31, 2023 | 1.25 Mn |
| Dec 31, 2022 | 1.25 Mn |